Immunotherapy plus chemo before surgery for hypopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus two chemotherapy drugs (TP regimen) before surgery for hypopharyngeal cancer that is locally advanced but hasn't spread. The goal is to shrink the tumor and improve surgical outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You are generally active and able to do light work (ECOG score 0 or 1).
- You are willing and able to have surgery to remove the tumor.
- You have hypopharyngeal cancer that has not spread to distant organs.
- Your major organs (liver, kidneys, blood) are working well enough.
- You have not had any prior cancer treatment for this condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy combined with an immunotherapy drug (finotonlimab) before surgery for locally advanced hypopharyngeal cancer. It aims to shrink the tumor enough to improve surgery outcomes.
This trial tests adding an immunotherapy drug (PD-1 inhibitor) to chemotherapy before surgery for advanced laryngeal or hypopharyngeal cancer. The goal is to see if this combination shrinks tumors more and improves outcomes for patients who need their entire voice box removed.
This trial tests a combination of an immunotherapy drug (penpulimab) with chemotherapy for people with advanced hypopharyngeal cancer that can still be removed with surgery. The goal is to see if this combination shrinks tumors and improves outcomes before surgery.
This trial tests a combination of three drugs (adebrelimab, carboplatin, and albumin-bound paclitaxel) before surgery for people with advanced mouth cancer that can be removed. The goal is to see if this treatment can help shrink the tumor and improve outcomes.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), dalpiciclib (a targeted therapy), and chemotherapy—given before surgery to shrink head and neck cancer tumors. The goal is to see if this treatment helps remove the cancer and improves outcomes.
This trial tests whether adding immunotherapy before surgery, followed by either radiation or organ-preserving surgery, can improve outcomes for people with locally advanced laryngeal or hypopharyngeal cancer. It may help avoid complete removal of the voice box.
Hear when a new Locally Advanced Hypopharyngeal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.